AMRN

Why Amarin Corporation Skyrocketed 23.9% in August

A man in a suit with rockets attached to his back shoots skyward.

What happened

Ahead of long-term outcomes data from its cardiovascular outcomes study of Vascepa in September, Amarin Corporation plc (NASDAQ: AMRN) shares increased by 23.9% in August, according to S&P Global Market Intelligence .

So what

Vascepa is a purified fish-oil pill that won FDA approval in 2012 to lower triglycerides in patients with very high triglyceride levels.

The company's sales of Vascepa have been hamstrung by the lack of proof that lowering triglyceride levels can directly reduce the likelihood of a major cardiovascular event, such as heart attack, stroke, or death. Yet Vascepa's revenue has been growing steadily, and in the second quarter, Amarin reported revenue of $52.6 million, up 16.4% year over year.

Earlier this year, Amarin reported that the final patient visit has occurred in its six-year outcomes study, and on Aug. 26, management said that the study is on track for "top-line results before the end of September 2018."

Now what

The stakes are high for Amarin. If its outcomes study is a success, then Vascepa could win considerably greater use, because there are roughly 3.8 million Americans with triglyceride levels of 500 to 2,000 mg/dl. Alternatively, if the trial fails, then sales could dwindle, casting a shadow over Amarin's future. Although sales have been climbing, Amarin lost $68 million on revenue of $181 million in 2017.

Overall, Vascepa's trial could go either way, and the binary nature of the trial and resulting impact on the company's financial condition means this stock is only suitable for aggressive and risk-tolerant investors.

10 stocks we like better than Amarin

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Amarin wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of August 6, 2018

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.